Detailed results from one of AstraZeneca's key lung cancer trials released on Monday showed that its experimental precision ...

KEY TAKEAWAYS A Phase 3 trial found AstraZeneca's experimental lung cancer drug datopotamab deruxtecan did not significantly ...

AstraZeneca’s Phase 3 study in bladder cancer, showed that giving Imfinzi — before and after surgery — cut the risk of death.

AstraZeneca Plc shares are on track for their biggest weekly decline since July 2023, after a disappointing update for the ...

The share price of AstraZeneca took a big hit on Tuesday after investors reacted to disappointing news from the company's ...

AstraZeneca's Dato-DXd faces challenges in overall survival data but holds potential for approval with promising PFS benefits ...

AstraZeneca has used artificial intelligence to devise a unique biomarker for its Daiichi Sankyo-partnered datopotamab ...

London-listed AstraZeneca shares fell more than 5% on Tuesday after results from the company's lung cancer trials showed that ...

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...

AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...

The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...

Shares in AstraZeneca dropped nearly 5 per cent on Tuesday after its failure to hit a target in trials for a next-generation ...